ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / QGEN
KYMR (50) RGEN (64) PCVX (49) KRYS (72) ⌘ Pro Terminal β†’

Qiagen N.V. (QGEN) β€” RQD Stock Rating Cockpit

$50.22 -0.24% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $50.32

Qiagen N.V. (QGEN) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (62% profit margin, 8% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

πŸ“Š Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY β€’ 68.4% hit rate) β†’
ROARABLE B- β€’ BUY Cap $10.37B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on QGEN Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is QGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Qiagen N.V. (NYSE: QGEN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $50.22 (-0.24% 1D, market cap $10.37B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, QGEN ranks #78 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does QGEN compare to KYMR and RGEN in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), QGEN carries a Roarable B- (71/100 RQD), trailing P/E of 24.4x, gross margin of 62.2%, and ROIC of 8.0%. By comparison, KYMR (Kymera Therapeutics Inc.) holds a D grade (50/100 RQD, P/E 32.7x, ROIC -21.4%, cap $10.19B) and RGEN (Repligen Corporation) posts a C grade (64/100 RQD, P/E N/A, ROIC 2.3%, cap $10.69B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for QGEN?
β–Ό

Per QGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001015820), Qiagen N.V. generated $2.09B in revenue (+5.7% YoY), $424.9M in net income, and $453.3M in free cash flow against $6.28B in total assets and $1.65B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $50.32 (+0.20%)🧬 Cannibal Buyback (-2.08% YoY Shares)βš™οΈ Cash Engine: 11/20 (D+) β€’ 21.7% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY β€’ 68.4% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERBUY β€’ B-
025507510071
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B- Β· Rk B
Cash (11)Whales (16)SEC (16)Macro (13)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+5.9% Base Target
$63 Bull$53 Base$41 Bear
πŸ“¬ FREE QGEN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for QGEN)Realized 20D OHLCV Swing Band: Β±4.2%
Deterministic 5-Pillar Attribution (71/100 Composite)
πŸ” WHY QGEN SCORES 71/100 (B-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+16/20 pts (23% of score)

20D Institutional Volume Accumulation (Β±4.2% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (23% of score)

Altman Z-Score 3.54 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 9/9

β–Ό #1 Drag / Risk Factor: Cash Engine Quality11/20 pts (-9 pt drag)

Capital intensity & 22.3% operating margin leave 9 pts on the table

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
63
Grade C+$45.44+7.6% Next Q
Q2 (-2Q)
66
Grade B-$48.90+2.6% Next Q
Q3 (-1Q)
68
Grade B-$50.17+0.1% Next Q
Current
71
Grade B-$50.22+6.8% Hist 90D Ξ±
Trajectory: C+ (63) β†’ B- (71)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the QGEN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 71/100 (B-) score, QGEN faces multiple-compression risk if 24.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) β€” any gross margin slip below 59.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($45.41) or 200D SMA ($42.62) invalidates the momentum regime and cuts Target Base ($53.16) toward Bear Floor ($41.18).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QGENβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œQGEN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 71%NO 29%Trade / Inspect Odds β†’
RSI-14 MOMENTUMOVERBOUGHT (>70)
72.430 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.54>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE70% OF RANGE
L: $33$50.22H: $58
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (62% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: D+RQD 11 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: B+RQD 31 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 29 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on QGEN

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (55)

8.0% ROIC with 62.2% gross margin and 4.37% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 3.54 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (73)

31/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like QGEN
  • βœ“Big institutional funds and options desks are actively positioning on the bullish side.
  • βœ“Company leadership has skin in the game with net positive insider conviction.
  • βœ“Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (QGEN Tape Review)

  • βœ“Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • βœ“Forensic Red-Light accounting & dilution traps to review on your watchlist
  • βœ“Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
QGEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.88%β–² ASCENDING CHANNEL
2026-11-02O $50.33H $50.34L $50.22C $50.22VOL 3.55M
RES: $52.61SUP: $42.57SMA50: $45.41SMA200: $42.62
$52.10$46.80$41.49$36.19$30.88RES $52.61SUP $42.57$50.222026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QGEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ QGEN Butterfly Map β†’ + Track QGEN β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
18.1%/yr Implied 5Y Growth

vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on QGEN today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for QGEN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QGEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QGEN)

Health Care Rank #78 of 1016 βš”οΈ KYMR vs QGEN Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (QGEN vs. KYMR, RGEN, PCVX, KRYS)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Qiagen N.V. (QGEN) ranks #78 by composite RQD confidence (71/100, grade B-) and #109 by equity capitalization ($10.37B). Within this direct 5-issuer industry benchmark cohort, QGEN leads on earnings valuation at 24.4x trailing P/E, while KRYS leads on capital efficiency and profitability with 16.5% ROIC and β€” gross margin. KRYS currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with QGEN at 71/100 (B-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
QGEN ACTIVE
Qiagen N.V.
B- 71/100 24.4x 62.2% 8.0% -0.24% $10.37B Benchmark Subject
KYMR
Kymera Therapeutics Inc.
D 50/100 32.7x β€” -21.4% +3.29% $10.19B /kymr-vs-qgen β†’
RGEN
Repligen Corporation
C 64/100 β€” 88.2% 2.3% -6.20% $10.69B /rgen-vs-qgen β†’
PCVX
Vaxcyte Inc.
D 49/100 β€” β€” -27.6% -0.93% $9.85B /pcvx-vs-qgen β†’
KRYS
Krystal Biotech Inc.
B 72/100 46.9x β€” 16.5% +2.38% $9.61B /krys-vs-qgen β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001015820

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Qiagen N.V. (QGEN) reported GAAP revenue of $2.09B (+5.7% vs. FY2024 revenue of $1.98B , and +6.3% cumulative change since FY2023) , GAAP net income of $424.9M, operating cash flow of $654.3M, and free cash flow of $453.3M (-10.5% YoY). On the balance sheet, QGEN closed FY2025 with $6.28B in total assets against $1.65B in total debt (Altman Z-Score: 3.54, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.09B $424.9M $654.3M $453.3M $6.28B $1.65B
FY2024 (FY) 2024-12-31 $1.98B $83.6M $673.6M $506.4M $5.69B $839.7M
FY2023 (FY) 2023-12-31 $1.97B $341.3M $459.5M $371.0M $5.71B $1.34B

3. QGEN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Qiagen N.V. (NYSE: QGEN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $50.22 (-0.24% 1D, market cap $10.37B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, QGEN ranks #78 in composite RQD confidence.

How does QGEN compare to KYMR and RGEN in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), QGEN carries a Roarable B- (71/100 RQD), trailing P/E of 24.4x, gross margin of 62.2%, and ROIC of 8.0%. By comparison, KYMR (Kymera Therapeutics Inc.) holds a D grade (50/100 RQD, P/E 32.7x, ROIC -21.4%, cap $10.19B) and RGEN (Repligen Corporation) posts a C grade (64/100 RQD, P/E N/A, ROIC 2.3%, cap $10.69B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QGEN?

Per QGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001015820), Qiagen N.V. generated $2.09B in revenue (+5.7% YoY), $424.9M in net income, and $453.3M in free cash flow against $6.28B in total assets and $1.65B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QGEN trading relative to its 50-day, 200-day, and 52-week technical levels?

QGEN last traded at $50.22 (-0.24% on volume of 4,168,167 shares), positioning the stock +10.59% above its 50-day simple moving average ($45.41) and +17.83% above its 200-day simple moving average ($42.62). Across its 52-week range of $32.53 to $57.82, QGEN sits at the 69.9% percentile with a 14-day RSI of 72.4 (OVERBOUGHT (>70)) and an implied next-earnings move of Β±4.2% ($48.11 to $52.33).

QGEN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Should I buy, hold, or sell QGEN stock right now?

Qiagen N.V. (QGEN) currently earns a Roarable Rating of B- (Buy β€” BUY) with 71/100 RQD Confidence. High-quality cash engine (62% profit margin, 8% return on capital) with steady institutional support.

What is QGEN's 12-month price target and RQD AI Jury consensus?

QGEN's 12-month base price target is $53.16 (range $41.18 to $62.73), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: QGEN RQD Cockpit QGEN 12M Forecast QGEN Earnings & Move QGEN Dividends & DRIP QGEN Insiders & 13F QGEN Whale Options QGEN Profit Sankey QGEN News & Why
ROARABLE RATING BRIEF β€’ RQD 71/100 (B-) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

QGEN β€” Qiagen N.V.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:16:25Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD Score is 71 out of 100, graded B- and labeled "Roarable Buy β€” Sound Institutional Accumulation," per the Roarable RQD rating. Across its five pillars:

  • Fundamental Cash Engine: 11 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 8% and an FCF yield of 4.37%. Modest returns on capital and a moderate cash yield at the current price are the main limits on this score.
  • Whale 13F Flow: 16 / 20. Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning. It is one of the stronger components, though the underlying 13F holder detail is not available in source data.
  • Insider Conviction: 15 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The individual transactions are not itemized in the source data.
  • Macro Regime Fit: 13 / 20. Per the Roarable RQD rating, this pillar reflects a Beta of 0.95 and sector sensitivity. A beta near 1.0 implies market-like volatility rather than a defensive or aggressive profile.
  • Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, this pillar reflects an Altman Z of 3.54, a Piotroski F of 9/9, and Debt/Equity of 0.44. These are the strongest forensic readings in the rating.

For a prospective investor, the rating suggests that balance-sheet quality and institutional/insider flow are the primary supports, while cash-generation efficiency (ROIC of 8%) and macro sensitivity are the weaker links. The stock's trading at $50.34 sits within a 52-week range of $32.53 to $57.82 per the market data, so the position relative to that range is a valuation context point rather than a signal in itself. The recent news flow (see Catalysts) includes a takeover-related item that could dominate near-term price action independent of these pillars. This is an analytical summary, not personalized financial advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
$50.34$10.37B24.422.717.62.060.52%0.95$32.53 - $57.828%

Business

Qiagen N.V. (QGEN) is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the company profile. Per the SEC financials, the company reported revenue of $2090.0M for FY 2025. Not available in source data for product lines, customer base, or detailed revenue model.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$2090.0M$465.9M$424.9MN/A$453.3M$839.0M$1654.4M
FY 2024$1978.2M$97.7M$83.6MN/A$506.4M$663.6M$839.7M
FY 2023$1965.3M$409.9M$341.3MN/A$371.0MN/A$1335.1M

Per the market data, gross margin is 62.2%, operating margin 22.3%, and net margin 20.3%, with ROIC of 8%. Per the Roarable RQD rating, the Altman Z-Score is 3.54 and the Piotroski F-Score is 9/9. Debt/Equity is 0.44 per the Roarable RQD rating. Debt rose from $839.7M in FY 2024 to $1654.4M in FY 2025 per the SEC financials, while cash rose from $663.6M to $839.0M over the same period.

Recent Catalysts & News Wire Analysis

  • GREEN / CATALYST: "Qiagen shares surge on report of advanced EQT takeover talks" (Yahoo Finance, 1h ago per the news feed).
  • YELLOW / MARKET WIRE: Technical breakout setup (ChartMill); options positioning commentary (TradingView); GF Score of 76/100 with a 5.0% price move (GuruFocus).
  • RED / RISK WATCH: "Qiagen: Unanimous Acceptance Takeover Nears Close (Rating Downgrade)" (Seeking Alpha, 12h ago per the news feed). This item carries a downgrade and a deal-closing framing.
  • YELLOW / MARKET WIRE: Halper Sadeh LLC investigation item (The National Law Review).

Per the Butterfly Supply-Chain Graph, supply_chain is listed as NONE, with no butterfly links and no proprietary signals. Not available in source data for additional supply-chain signal.

Open Questions

  • What are the terms, status, and parties of the takeover talks referenced in the catalyst headlines, and does the "Unanimous Acceptance" item refer to the same transaction?
  • What drove the increase in debt from $839.7M to $1654.4M between FY 2024 and FY 2025, and how is it being serviced?
  • What are the EPS figures, since the reported EPS values are N/A across all periods?
  • Who are the institutional and insider holders behind the Whale and Insider pillar scores?
  • What is the nature of the Halper Sadeh LLC investigation referenced in the news feed?

QGEN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Qiagen N.V. (QGEN) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to QGEN Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

QGEN Bull vs. Bear Conversation Board β€” What's Your Call at $50.22?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON QGEN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on QGEN:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk πŸ‚ BULLISH 🎯 Target: $59.40 (+18.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is QGEN (B- β€’ RQD 71/100) a Buy at $50.34?

Welcome to the QGEN (Qiagen N.V.) Roar Pit. Current RQD Composite is 71/100 (Roarable Buy β€” Sound Institutional Accumulation) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $40.27 (-20.0%)
Spot @ $50.34

Pump the brakes on QGEN β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on QGEN, but look at what you are paying: 24.4x trailing P/E with 62.2% gross margins. Unless Qiagen N.V. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $59.40 (+18.0%)
Spot @ $50.34

QGEN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on QGEN, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $50.34 (52-wk range $32.53 - $57.82), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%